Drug Trial Radar · NCT06770465
Maternal Use of Antibiotics and the Risk of Congenital Malformations
Last checked: Nov 19, 2026Latest source record: Jan 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
850,000
Actual
Start
Jun 1, 2024
Primary completion
Jun 30, 2025
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- West China HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 13, 2025
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 14 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Antibiotics are widely used during pregnancy to prevent or treat infections, yet concerns remain regarding their fetal safety. Drawing on data from spontaneous reporting databases and cohort studies, this study aims to explore potential associations between exposure to various antibiotic classes during pregnancy and congenital malformations. Data were collected from publicly available reports in the U.S. Food and Drug Administration's Adverse Event Reporting System (FAERS), the Canada Vigilance Adverse Reaction (CVAR) database, and a population-based retrospective cohort in Xiamen, China. By applying multiple signal detection methods, we identified potential risk signals linking different antibiotic classes to organ-system-specific congenital malformations. For antibiotics showing positive signals, we further utilized a pregnancy medication cohort in Xiamen and applied causal inference techniques to estimate the adjusted relative risk of congenital malformations associated with first-trimester exposure to these antibiotics. Several sensitivity analyses-including both negative- and positive-control analyses-will also be performed.
Conditions
- Congenital Malformations
Interventions
Different categories of antibioticsDrug
Use of different categories of antibiotics during pregnancy, such as quinolones and macrolides.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Congenital malformationsTime frame: From pregnancy to 42 days after delivery
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The West China Hospital of Sichuan university
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.